Vinge advises EQT Healthcare Growth, a new dedicated healthcare buy-out strategy introduced by EQT, in connection with its first investment – the acquisition of the biotech company, Mabtech, from IK Small Cap II Fund and several minority sellers.
EQT Healthcare Growth is a new buy-out strategy that builds on EQT’s 30-year healthcare track record, focused on scaling innovative, fast-growing healthcare companies to help deliver positive outcomes across the value chain. By helping companies build commercial muscle and expand their global reach, the strategy aims to enable the development of medical research, diagnostics, tools and treatments to deliver more efficient and accessible healthcare.
Mabtech is a category leading provider of tests and kits for studying immune responses predominantly in vaccine, infectious diseases, and oncology research. The company is based in Sweden and has over 900 customers in more than 60 countries. EQT Healthcare Growth will support Mabtech as it looks to expand its scale and reach.
The transaction is subject to customary conditions and approvals and is expected to close in Q1 2024.
Vinge’s team consisted of Christina Kokko, Johanna Wiberg, Viktor Lennartsson, Robin Sultani and Filip Magnusson (M&A), Stojan Arnerstål and Rebecka Målquist (IPR), Louise Brorsson Salomon, Helena Göransson, Kamyar Najmi and August Ahlin (Financing), Christoffer Nordin and Rebecka Danelius Gedin (Agreements and Permits), Mika Jordan and Elis Allmark (IT), Nicklas Thorgerzon and Lisa Hörnqvist (GDPR), Gulestan Ali (Employment), Kristoffer Larson (Real Estate), Mia Falk, Sam Fakhraie Ardekani and Maja Höglund (Compliance and Sanctions), Sebastian Örndahl, Daniel Wendelsson, Dagne Sabockis, Lovisa Lewin and Hilda Ivarson (Regulatory) and Gabriella Balbo (Transaction Support Coordinator).
